Volume 8.20 | May 26

Cord Blood News 8.20 May 26, 2016
Cord Blood News
     In this issue: Publications | Reviews | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  CBN on Twitter
The Association of Prenatal Exposure to Perfluorinated Chemicals with Glucocorticoid and Androgenic Hormones in Cord Blood Samples: The Hokkaido Study
Investigators examined the relationship between prenatal exposure to perfluorooctane sulfonate/perfluorooctanoate and cord blood levels of glucocorticoid and androgenic hormones. [Environ Health Perspect] Abstract | Full Article
Learn more about our standardized tools for cord blood banking
PUBLICATIONS (Ranked by impact factor of the journal)
Outcomes of Unrelated Cord Blood Transplantation in Patients with Multiple Myeloma: A Survey on Behalf of Eurocord, the Cord Blood Committee of Cellular Therapy and Immunobiology Working Party, and the Chronic Leukemia Working Party of the European Society for Blood and Marrow Transplantation
The authors retrospectively analyzed 95 patients, 85 with multiple myeloma and 10 with plasma cell leukemia, receiving single or double umbilical cord blood transplantation from 2001 to 2013. [Haematologica] Abstract

Low Oxygen Tension Reveals Distinct HOX Codes in Human Cord Blood-Derived Stromal Cells Associated with Specific Endochondral Ossification Capacities In Vitro and In Vivo
The expression of 39 human HOX genes was determined in neonatal cord blood stromal cells and linked to differentiation-associated signatures. In cord blood, unrestricted somatic stromal cells, lacking HOX gene expression, and cord blood-derived multipotent stromal cells, expressing about 20 HOX genes, are distinguished by their specific HOX code. [J Tissue Eng Regen Med] Abstract

Brentuximab Vedotin in Combination with or without Donor Lymphocyte Infusion for Patients with Hodgkin Lymphoma after Allogeneic Stem Cell Transplantation
Researchers evaluated the safety and efficacy of Brentuximab vedotin with or without the addition of donor lymphocyte infusion after allogeneic stem cell transplantation in 16 patients with advanced Hodgkin lymphoma. [Bone Marrow Transplant] Abstract

Changing Trends of Unrelated Umbilical Cord Blood Transplantation (UCBT) for Hematological Diseases in Patients Older Than 50 Years: An Eurocord – CIBMTR Survey
Scientists conducted a registry-based survey to evaluate the use of umbilical cord blood transplantation in patients aged 50 years and older, both in Europe and North America. [Biol Blood Marrow Transplant] Abstract

Atomized Human Amniotic Mesenchymal Stromal Cells for Direct Delivery to the Airway for Treatment of Lung Injury
Researchers demonstrated that human amniotic mesenchymal stromal cells are able to survive after being sprayed onto substrates with different stiffness, especially in the presence of collagen I. [J Aerosol Med Pulm Drug Deliv] Abstract

Hepatitis B Virus Replication in CD34+ Hematopoietic Stem Cells From Umbilical Cord Blood
The susceptibility of CD34+ hematopoietic stem cells (HSCs) to hepatitis B virus (HBV) was investigated. Cord blood-derived CD34+ HSCs were exposed to HBV in vitro, and immunocytochemistry, transmission electron microscopy, and RT-PCR were used to identify viral-related proteins and specific viral genomic sequences. [Med Sci Monit] Abstract

Learn more about MegaCult™-C collagen-based medium for colony-forming unit - megakaryocyte (CFU-Mk) assays of human or mouse hematopoietic progenitor cells.
Chronic Myeloid Leukemia in the Era of Tyrosine Kinase Inhibitors: An Evolving Paradigm of Molecularly Targeted Therapy
The author provides an overview of the current understanding of chronic myeloid leukemia pathogenesis, recommendations for diagnostic tools, treatment strategies and management guidelines, and highlights the breakpoint cluster region-abelson-dependent and -independent mechanisms that contribute to the development of resistance to tyrosine kinase inhibitors. [Mol Diagn Ther] Abstract

Visit our reviews page to see a complete list of reviews in the cord blood research field.
NYBC’s Laboratory of Complement Biology Receives NIH Grant to Study “Mechanisms Controlling Transfusion-Associated Antibody Responses in Sickle Cell Disease”
The New York Blood Center’s (NYBC) Laboratory of Complement Biology has received a $2.3 million grant from the National Institutes of Health (NIH) to study mechanisms to control successful transfusions in patients with sickle cell disease. [New York Blood Center] Press Release

Gamida Cell Announces $4.4 Million Grant from the Israeli Government
Gamida Cell announced it has been awarded a grant of up to $4.4 million from the Israel Innovation Authority of the Israeli Ministry of Economy and Industry. [Gamida Cell] Press Release

Opdivo® (Nivolumab) Granted First Approval of a PD-1 Inhibitor in Hematology for the Treatment of Classical Hodgkin Lymphoma Patients Who Have Relapsed or Progressed After Auto-HSCT and Post-transplantation Brentuximab Vedotin by the FDA1
Bristol-Myers Squibb Company announced the U.S. Food and Drug Administration (FDA) has approved Opdivo® for the treatment of patients with classical Hodgkin lymphoma who have relapsed or progressed after autologous hematopoietic stem cell transplantation (auto-HSCT) and post-transplantation brentuximab vedotin. [Bristol-Myers Squibb Company (Business Wire)] Press Release

From our sponsor: Learn how to form and isolate neural rosettes more efficiently. Watch the video.
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
NEW 2nd Annual Cell & Gene Therapy Congress 2016
November 3-4, 2016
London, United Kingdom

Visit our events page to see a complete list of events in the cord blood community.
NEW Research Assistants and Associates – Leukemia and Stem Cell Biology (King’s College London)

Scientific Communications and Publishing Coordinator (STEMCELL Technologies Inc.)

Technical Sales Representative (STEMCELL Technologies Inc.)

Postdoctoral Research Associate – Myeloid Leukemia (Upstate Medical University)

Postdoctoral Studies – Computational Transcriptomics and Epigenomics in Acute Myeloid Leukemia (Karolinska Institutet)

Postdoctoral Positions – Stem Cell Biology and Regenerative Medicine (University of Southern California)

Postdoctoral Research Associate – TAM-Family Kinases in Leukemogenesis (Emory University)

Postdoctoral Fellow – Hematopoietic Stem Cells (University of Pennsylvania)

Principal Investigator – Stem Cell Biology and Regeneration Medicine (Guangzhou Women and Children’s Medical Center)

Associate Scientist – Hematopoietic Stem Cell Biology (Editas Medicine)

Postdoctoral Fellow – Hematology/Oncology (Boston Children’s Hospital)

Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Cord Blood News? Click here to submit!

Comments or suggestions? Submit your feedback here
Learn more about Cord Blood News: Archives | Events | Contact Us